0 patents currently held, every record listed here
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
This portfolio holds none of the 5 US patents in force on its record. from the record
Of the 5 now held by other companies, 5 name Metagenics LLC as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end
When these terms end
Each bar runs from grant to computed term end. 2011 to 2033.
US 7,914,831
Synergistic Anti-Inflammatory Pharmaceutical Compositions and Related Methods Using Curcuminoids or Methylxanthines
no later than Feb 15, 2027
US 8,815,306
Methods and Compositions for Promoting Bone and Joint Health
no later than Mar 14, 2028
US 10,220,068
Phytonutrient Compositions and Methods to Protect Against Radical Mediated Cellular and DNA Damage
May 27, 2033
20162021202620312033
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends no later than Feb 2027 · Medium confidence
The most cited patent in this portfolio, cited by 24 later US patents, top 25% of utility patents granted in 2011 in our data. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Metagenics LLC
Also notable
Ends Feb 2028 · High confidence
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2028. A terminal disclaimer caps this term to an earlier patent's.
now held by Metagenics LLC
Also notable
Ends May 2033 · High confidence
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2033.
now held by Metagenics LLC
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first.
Also on record: 5 patents in force now held by others · 35 patents ended · 43 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
8 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.